Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

Leukemia. 2009 Jun;23(6):1193-6. doi: 10.1038/leu.2009.32. Epub 2009 Feb 26.

Authors

D Rea, G Etienne, S Corm, P Cony-Makhoul, M Gardembas, L Legros, V Dubruille, S Hayette, F-X Mahon, J-M Cayuela, F E Nicolini

PMID: 19242496
DOI: 10.1038/leu.2009.32

No abstract available

Publication types

Letter

MeSH terms

Benzamides
Dose-Response Relationship, Drug
Humans
Imatinib Mesylate
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Maximum Tolerated Dose
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*

Substances

Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate